Live biotherapeutics change the pharma landscape
Interviewee/Contributor
Duncan Peyton
Organisation
4D pharma Plc
Cancer (Oncology)
ASCO 2021- Oncology developers disclose their latest data
Interviewee/Contributor
Victoria English
Organisation
MedNous
Oncology approvals rise, driven by novel compounds
Interviewee/Contributor
Bruno Pagliara
Organisation
MedNous
Hot targets in immuno-oncology
Interviewee/Contributor
Eliot Forster
Organisation
F-star Therapeutics Inc
The Bispecific Approach, Interviews with Merus, Genmab and NovalGen
Interviewee/Contributor
Bill Lundberg, Tahamtan Ahmadi and Amit Nathwani
Organisation
MedNous
Why we should take a second look at RNA therapeutics
Interviewee/Contributor
Gabriele Campi
Organisation
AurorA Science
Technology Transfer: Partnering with the US National Cancer Institute
Interviewee/Contributor
Michael Salgaller, Michele Newton and Michael Pollack
Organisation
US National Cancer Institute
Building biotech using an oncology network
Interviewee/Contributor
Jónas Einarsson
Organisation
Oslo Cancer Cluster, Radforsk
Drug development robust, despite the pandemic
Interviewee/Contributor
Bruno Pagliara
Organisation
MedNous
Developing radionuclide PARP inhibitors
Interviewee/Contributor
Greg Mullen
Organisation
Theragnostics Ltd